Related Experiment Videos
Mediastinal Hodgkin's disease--a retrospective analysis
R Obrist1, M Battegay, J P Obrecht
1Department of Internal Medicine of the University, Kantonsspital, Basel, Switzerland.
Onkologie
|June 1, 1988
Summary
Multimodality therapy significantly improved survival for patients with mediastinal Hodgkin's disease. Older age and systemic symptoms were associated with poorer outcomes in this retrospective analysis.
Area of Science:
- Oncology
- Hematology
Background:
- Hodgkin's disease is a cancer of the lymphatic system.
- Mediastinal involvement is a common presentation.
- Prognostic factors require further investigation.
Purpose of the Study:
- To retrospectively analyze prognostic factors influencing survival in mediastinal Hodgkin's disease.
- To evaluate treatment outcomes based on therapy modalities.
Main Methods:
- Retrospective analysis of 37 patients with mediastinal Hodgkin's disease treated between 1972-1982.
- Evaluation of patient characteristics, prognostic factors, and survival rates.
- Comparison of outcomes based on treatment modalities (multimodality, radio-, or chemotherapy).
Main Results:
- Older age and systemic symptoms were linked to decreased survival.
- Mediastinal bulk disease was present in 44% of patients, with 66% in remission.
- Multimodality therapy demonstrated significantly better survival compared to single-modality treatments.
- No significant difference in survival was observed compared to patients without mediastinal involvement.
Conclusions:
- Multimodality therapy is a key factor for improved survival in mediastinal Hodgkin's disease.
- Age and systemic symptoms are important prognostic indicators.
- Further research into optimal treatment strategies for mediastinal Hodgkin's disease is warranted.